Trial Profile
Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary) ; Celecoxib
- Indications Musculoskeletal pain
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development
- 23 May 2016 Planned End Date changed from 1 Jan 2018 to 1 Sep 2016.
- 23 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2016.
- 21 Apr 2016 Status changed from discontinued to active, no longer recruiting.